CRBP

Corbus Pharmaceuticals Holdings

CRBP

Attention (50-day avg)0%

Attention rank (50-day avg)#833

Bullish sentiment (50-day avg)73%

Price to earnings ratio-1.17

Market capitalization133.8M

Earnings per share-6.11

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-78.5M

Social

What share of all stock conversation is about CRBP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Sep 15

Corbus Pharmaceuticals ($CRBP) is developing an obesity pill that showed a 5% mean weight loss at 12 weeks with no plateau in a Phase 1b study.
The company's obesity pipeline was previously considered a non-factor, but recent data selected for a late-breaking presentation at ObesityWeek26 has made it more attractive, trading around cash value and previous insider buy levels.
$CRBP's stock has experienced a parabolic fall over the past 8 days, with massive trading volume, and has set up momentum with consecutive red bars, down over 13% in the early trading session.

Generated by AI

Sentiment

Of the messages about CRBP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	64.16% -32.9	75% -5.15
Bearish	—	—	35.84% +32.9	25% +5.15

Bullish· Sep 11

The company's stock price has shown a significant increase, with a $2/share spiker and a $1+/share from the first consolidation zone, indicating a strong market reaction to recent news.
The company's recent tweets suggest a positive sentiment, with language that implies they are leaning into good data, not bracing for bad, which could lead to a very interesting Monday.
The stock's price target estimates are highly bullish, with an average target of ~$35.00, a high forecast of $48.00 to $52.00, and a low forecast of $17.00 to $28.00, indicating a strong potential for growth.

Bearish· May 26

$CRBP's data release led to a significant drop, indicating a possible disconnect between the market and the company's fundamentals.
The company's small float and low market capitalization make it vulnerable to short selling and potential dilution, which may impact its stock price.
The market's bearish reaction to Corbus Pharmaceuticals' data release suggests that investors are increasingly skeptical of small-cap biotech companies, which may be a sign of a broader market trend.

Generated by AI

Topics

Of the messages about CRBP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	0%	43.37%	74.56%
Analysts	0%	0%	11.24%	9.73%
Earnings	0%	95.45%	12.85%	3.99%
Technical Analysis	100%	4.55%	22.49%	8.68%
Macro	0%	0%	10.04%	2.93%
Controversies	0%	0%	0%	0.12%

Earnings· Aug 8

Corbus Pharmaceuticals reported Q2 2018 financial results, beating EPS loss estimates by $0.01.
The company reported a loss of $0.21, missing revenue estimates.
The earnings report was released pre-market, with Corbus Pharmaceuticals Holdings, Inc. being the main subject of discussion.

Analysts· Apr 5

Analyst Maury Raycroft of Jefferies has a top 7% ranking in the country and initiated coverage of CRBP with a $18 price target.
Raycroft has a strong track record, as seen in his initiation of ARWR at $6.50 with a $10 price target, which resulted in a stock price of $19 one year later.
CRBP has received multiple initiations with buy ratings and price targets ranging from $18 to $38, with Jefferies analyst Maury Raycroft's $18 target being close to a triple.

Announcements· Apr 7

Corbus Pharmaceuticals has announced broad alignment with the FDA on the registration path for CRB-701 in second-line HNSCC and cervical cancer.
The alignment enables Corbus to proceed with its proposed registrational study design and endpoints to support potential accelerated approval for CRB-701.
Corbus will present updated clinical data from the Phase 1/2 study of CRB-701 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

Technical Analysis· Jan 26

$CRBP may see a reversal candle, potentially the last chance for a trade.
The RSI for $CRBP has cooled off, and the stock may consolidate or gap fill after a strong day.
$CRBP could reach $75-80 on Monday or Tuesday, showing a strong break-up trend and a possible bull flag forming.

Generated by AI

Community

Of the messages about CRBP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	12%	45.83%	52.66%
Newcomers	100%	88%	54.17%	47.34%

Regulars· Sep 14

The CANYON-1 study of CRB-913, a daily oral CB1 inverse agonist, demonstrated statistically significant and clinically meaningful weight loss of 5% at 60 mg after 12 weeks with no plateau observed.
The treatment was generally well-tolerated, with psychiatric adverse events broadly in line with GLP-1 drugs and a favorable emerging GI tolerability profile, supporting the potential emergence of a new class of oral non-incretin obesity medicines.
The study results suggest that CRB-913 may offer meaningful weight loss with a differentiated tolerability profile, potentially establishing a new class of oral non-incretin obesity medicines.

Newcomers· Sep 15

Newcomers are focusing on the potential of Corbus Pharmaceuticals Holdings' obesity pill, citing a 5% mean weight loss at 12 weeks with no plateau and clean GI tolerability.
The newcomers are also discussing the asset's price performance, with some mentioning the potential for a dip before a rebound and others expressing frustration with the current price.
The newcomers are speculating about the future of Corbus Pharmaceuticals Holdings, with some predicting it will be acquired due to its potential in combination with other treatments.

Generated by AI

Incidence and prevalence of OPSCC continue to rise in the U.S. largely driven by HPV infection OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L+ setting in the U.S. with approximately 14,000 patients eligible for treatment annually NORWOOD, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that the first patient has been dosed in i

23h agoYahoo! Finance Canada

Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors

1d agoMarketWatch

Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors

4d agoMarketWatch

Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors

5d agoMarketWatch

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day

6d agoMarketWatch

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day

7d agoMarketWatch

Also Discussed

Investors talking about CRBP also mention

#	Name	Attention
1	ZYNE - Zynerba Pharmaceuticals, Inc.	——
2	CARA - Cara Therapeutics, Inc.	——
3	CBAK Energy Technology LimitedCBAT	0%0
4	Matinas BioPharma Holdings, Inc.MTNB	0.02%+0.02
5	SINO - Singularity Future Technology Ltd.	——
6	Aurinia Pharmaceuticals IncAUPH	0.01%+0.01
7	Palvella Therapeutics IncPIRS	0%0
8	Abeona Therapeutics Inc.ABEO	0%+0
9	BRQS - Borqs Technologies, Inc.	——
10	MACK - Merrimack Pharmaceuticals, Inc.	——

Corbus Pharmaceuticals Holdings, Inc.

Healthcare
Biotechnology

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for oncology and obesity. Corbus Pharmaceuticals Holdings, Inc. advances a pipeline centered on targeted treatments, including CRB-701, an antibody drug conjugate designed to target Nectin-4 on cancer cells, and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist being studied for obesity. The company’s work is concentrated on well-defined biological pathways and on creating medicines that address serious diseases through precision-focused mechanisms. Corbus Pharmaceuticals Holdings, Inc. plays a role in the biotechnology market as a developer of investigational drug candidates aimed at cancer and metabolic disease, with its current programs spanning clinical research and product development in these therapeutic areas.

Website

Location

500 River Ridge Drive

Norwood, MA, 02062

United States

Social

What share of all stock conversation is about CRBP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Sep 15

Corbus Pharmaceuticals ($CRBP) is developing an obesity pill that showed a 5% mean weight loss at 12 weeks with no plateau in a Phase 1b study.
The company's obesity pipeline was previously considered a non-factor, but recent data selected for a late-breaking presentation at ObesityWeek26 has made it more attractive, trading around cash value and previous insider buy levels.
$CRBP's stock has experienced a parabolic fall over the past 8 days, with massive trading volume, and has set up momentum with consecutive red bars, down over 13% in the early trading session.

Generated by AI

Sentiment

Of the messages about CRBP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	64.16% -32.9	75% -5.15
Bearish	—	—	35.84% +32.9	25% +5.15

Bullish· Sep 11

The company's stock price has shown a significant increase, with a $2/share spiker and a $1+/share from the first consolidation zone, indicating a strong market reaction to recent news.
The company's recent tweets suggest a positive sentiment, with language that implies they are leaning into good data, not bracing for bad, which could lead to a very interesting Monday.
The stock's price target estimates are highly bullish, with an average target of ~$35.00, a high forecast of $48.00 to $52.00, and a low forecast of $17.00 to $28.00, indicating a strong potential for growth.

Bearish· May 26

$CRBP's data release led to a significant drop, indicating a possible disconnect between the market and the company's fundamentals.
The company's small float and low market capitalization make it vulnerable to short selling and potential dilution, which may impact its stock price.
The market's bearish reaction to Corbus Pharmaceuticals' data release suggests that investors are increasingly skeptical of small-cap biotech companies, which may be a sign of a broader market trend.

Generated by AI

Topics

Of the messages about CRBP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	0%	43.37%	74.56%
Analysts	0%	0%	11.24%	9.73%
Earnings	0%	95.45%	12.85%	3.99%
Technical Analysis	100%	4.55%	22.49%	8.68%
Macro	0%	0%	10.04%	2.93%
Controversies	0%	0%	0%	0.12%

Earnings· Aug 8

Corbus Pharmaceuticals reported Q2 2018 financial results, beating EPS loss estimates by $0.01.
The company reported a loss of $0.21, missing revenue estimates.
The earnings report was released pre-market, with Corbus Pharmaceuticals Holdings, Inc. being the main subject of discussion.

Analysts· Apr 5

Analyst Maury Raycroft of Jefferies has a top 7% ranking in the country and initiated coverage of CRBP with a $18 price target.
Raycroft has a strong track record, as seen in his initiation of ARWR at $6.50 with a $10 price target, which resulted in a stock price of $19 one year later.
CRBP has received multiple initiations with buy ratings and price targets ranging from $18 to $38, with Jefferies analyst Maury Raycroft's $18 target being close to a triple.

Announcements· Apr 7

Corbus Pharmaceuticals has announced broad alignment with the FDA on the registration path for CRB-701 in second-line HNSCC and cervical cancer.
The alignment enables Corbus to proceed with its proposed registrational study design and endpoints to support potential accelerated approval for CRB-701.
Corbus will present updated clinical data from the Phase 1/2 study of CRB-701 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

Technical Analysis· Jan 26

$CRBP may see a reversal candle, potentially the last chance for a trade.
The RSI for $CRBP has cooled off, and the stock may consolidate or gap fill after a strong day.
$CRBP could reach $75-80 on Monday or Tuesday, showing a strong break-up trend and a possible bull flag forming.

Generated by AI

Community

Of the messages about CRBP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	12%	45.83%	52.66%
Newcomers	100%	88%	54.17%	47.34%

Regulars· Sep 14

The CANYON-1 study of CRB-913, a daily oral CB1 inverse agonist, demonstrated statistically significant and clinically meaningful weight loss of 5% at 60 mg after 12 weeks with no plateau observed.
The treatment was generally well-tolerated, with psychiatric adverse events broadly in line with GLP-1 drugs and a favorable emerging GI tolerability profile, supporting the potential emergence of a new class of oral non-incretin obesity medicines.
The study results suggest that CRB-913 may offer meaningful weight loss with a differentiated tolerability profile, potentially establishing a new class of oral non-incretin obesity medicines.

Newcomers· Sep 15

Newcomers are focusing on the potential of Corbus Pharmaceuticals Holdings' obesity pill, citing a 5% mean weight loss at 12 weeks with no plateau and clean GI tolerability.
The newcomers are also discussing the asset's price performance, with some mentioning the potential for a dip before a rebound and others expressing frustration with the current price.
The newcomers are speculating about the future of Corbus Pharmaceuticals Holdings, with some predicting it will be acquired due to its potential in combination with other treatments.

Generated by AI

Corbus Pharmaceuticals Holdings

Social

Sep 15

Bullish· Sep 11

Bearish· May 26

Earnings· Aug 8

Analysts· Apr 5

Announcements· Apr 7

Technical Analysis· Jan 26

Regulars· Sep 14

Newcomers· Sep 15

Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer

Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors

Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors

Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day

Also Discussed

Corbus Pharmaceuticals Holdings, Inc.

Company Information

Location

Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer

Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors

Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors

Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day

Also Discussed

Social

Sep 15

Bullish· Sep 11

Bearish· May 26

Earnings· Aug 8

Analysts· Apr 5

Announcements· Apr 7

Technical Analysis· Jan 26

Regulars· Sep 14

Newcomers· Sep 15